Michael Egholm - 20 Mar 2026 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 Apr 2026, 21:55:05 UTC
Prior SEC filing
24 Feb 2026
Next SEC filing
22 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Michael Egholm by Hanjoon Alex Kim, Attorney-in-Fact

Key filing fact

Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 08 Apr 2026.

Key facts

  • This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
  • 5 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 08 Apr 2026, 21:55.

Change

  • Previous filing in this sequence was filed on 24 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559779 Primary reporting owner

Egholm Michael

Relationship
President & CEO, Director
Address
C/O STANDARD BIOTOOLS INC., 50 MILK STREET, 10TH FLOOR, BOSTON
Signature
/s/ Michael Egholm by Hanjoon Alex Kim, Attorney-in-Fact
Signature date
08 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Award

Transaction value
Shares
+1,042,373
Change %
+19%
Price
$0.000000*
Shares after
6,594,083
Date
20 Mar 2026
Ownership
Direct
Footnotes
F1
LAB transaction

Common Stock

Options Exercise

Transaction value
Shares
+196,513
Change %
+3%
Price
$0.000000*
Shares after
6,790,596
Date
06 Apr 2026
Ownership
Direct
LAB transaction

Common Stock

Tax liability

Transaction value
Shares
-95,014
Change %
-1.4%
Price
$0.9080*
Shares after
6,695,582
Date
06 Apr 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LAB transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares
+2,345,340
Change %
Price
$0.000000*
Shares after
2,345,340
Date
20 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,345,340
Exercise price
$0.9846
Footnotes
F3
LAB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-196,513
Change %
-100%
Price
$0.000000*
Shares after
0
Date
06 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
196,513
Exercise price
Footnotes
F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

Footnote F2

The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.

Footnote F3

The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F4

Each RSU represents the contingent right to receive one share of the Issuer's common stock.

Footnote F5

On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .